

CLEOPATRARX ANNOUNCES CEO TRANSITION PROCESS TO SUPPORT CONTINUED GROWTH AND NATIONAL MOMENTUM

May 1, 2025 — CleopatraRX™, a healthcare company focused on advancing cognitive and neurological health for women, is pleased to announce that it has initiated a Chief Executive Officer (CEO) transition plan. Effective as of April 30, 2025, Dina Leeds will no longer serve as CEO. The decision to initiate the search was made unanimously by the Board of Managers (the “Board”), driven by the company’s growth trajectory and the strategic leadership needed to capitalize on its current momentum. The CleopatraRX™ Board has formed a CEO Search Committee to identify a successor. Day-to-day operations will be managed by the existing leadership team to ensure continuity and continued progress across key initiatives.

“As CleopatraRX™ continues to gain national visibility and commercial traction, the Board determined that now is the right time to bring in a new CEO to lead the company through its next stage of growth,” said Kevin Murray, CFO of CleopatraRX and member of the Board. “Recent features on *The Today Show*, *The New York Times*, and *Oprah* have accelerated awareness of CleopatraRX™’s mission, and we are committed to identifying a leader who can scale our business, expand market access, and build lasting value.”

The CEO Search Committee will begin its work immediately and will seek candidates with strong operational, marketing, and fundraising experience, and a demonstrated commitment to advancing innovation in healthcare, particularly in women’s health. “CleopatraRX™ is well positioned, with a differentiated product and a strong customer response,” added Mr. Murray.

About CleopatraRx™

CleopatraRX™ is a women’s health company dedicated to improving brain health during menopause through targeted hormone replacement therapy. Its patented PearlPAK® treatment is the only menopause treatment designed to target cognition. With a personalized approach and integrated telehealth delivery, CleopatraRX is reshaping how women manage cognitive symptoms during midlife and beyond.